Vanguard Personalized Indexing Management’s NovoCure NVCR Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,528	Closed	-$259K	–	1488
2022 Q4	$259K	Sell	3,528 -4,045	-53%	-$304K	0.01%	1032
2022 Q3	$575K	Buy	7,573 +184	+2%	+$14.4K	0.03%	733
2022 Q2	$514K	Buy	7,389 +918	+14%	+$69.2K	0.02%	812
2022 Q1	$536K	Buy	+6,471	New	+$477K	0.03%	805
2021 Q3	–	Sell	-4,637	Closed	-$1.03M	–	1028
2021 Q2	$1.03M	Buy	+4,637	New	+$902K	0.11%	190

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Vanguard Personalized Indexing Management's NVCR Position: Q1 2023 in Review

Vanguard Personalized Indexing Management sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 3,528 shares — an estimated $259K sold.

Vanguard Personalized Indexing Management first reported a position in NVCR in Q2 2021 and held it in 5 quarters. The position peaked at $1.03M in Q2 2021. 295 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

Vanguard Personalized Indexing Management reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
Vanguard Personalized Indexing Management sold 3,528 NovoCure shares in Q1 2023, an estimated $259K.
Vanguard Personalized Indexing Management first reported a position in NovoCure in Q2 2021 and held it in 5 quarters.
Vanguard Personalized Indexing Management's NovoCure position peaked at $1.03M in Q2 2021.
295 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2023, filed 10 May 2023.